HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

J 111225

structure in first source

Also Known As:

J 111,225; J-111,225; J-111225

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - beta-Lactams: 2386
      - Carbapenems: 4837
        J 111225: 1
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - beta-Lactams: 2386
      - Carbapenems: 4837
        J 111225: 1

Experts

1.	Hashizume, T: 1 article (03/2000)
2.	Morishima, H: 1 article (03/2000)
3.	Nagano, R: 1 article (03/2000)
4.	Shibata, K: 1 article (03/2000)

Related Diseases

1.	Coinfection 03/01/2000 - "Against a mixed infection caused by MRSA and Pseudomonas aeruginosa, monotherapy with J-111,225 showed an ED(50) value of 7.23 mg/kg, whereas combined treatment with vancomycin plus imipenem (1:1) had an ED(50) of 20.86 mg/kg. J-111,225 showed good therapeutic efficacy against methicillin-susceptible S. "
2.	Infections 03/01/2000 - "Therapeutic efficacy of J-111,225, a novel trans-3,5-disubstituted pyrrolidinylthio-1beta-methylcarbapenem, against experimental murine systemic infections." 03/01/2000 - "In a murine model of systemic infection with methicillin-resistant Staphylococcus aureus (MRSA), J-111,225 showed an ED(50) value of 5. 83 mg/kg, which was comparable to vancomycin (ED(50) 4.84 mg/kg), whereas imipenem failed to cure infected mice (ED(50) >100 mg/kg). "

Related Drugs and Biologics

1.	Imipenem
2.	Vancomycin
3.	Methicillin (Metin)